H-1B sponsorship profile: Imbrium Therapeutics LP. Across U.S. Department of Labor LCA disclosures, Imbrium Therapeutics LP filed 3 Labor Condition Applications covering 3 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (3 certified of 3 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Imbrium Therapeutics LP’s H-1B petitions range from $130,000 at the low end to $150,128 at the high end, with a petition-weighted average of $136,709. That range reflects the mix of occupations the company sponsors, led by Senior Manager, Regulatory Strategy (3 petitions at $136,709 avg). H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Imbrium Therapeutics LP is headquartered in Stamford, CT under NAICS code 32541, and places H-1B workers across 1 state, most heavily in RI. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Imbrium Therapeutics LP ranks. By H-1B petition volume, Imbrium Therapeutics LP is #37,433 of 119,880 employers nationally and #388 of 1,323 employers headquartered in CT. Both ranks are computed live from the same underlying petition counts, not a separate estimate.